The nuclear transcription factor NF-κB plays a significant role in the pathogenesis of a variety of diseases. Because of the key role played by the inhibitor of κB kinase (IKK) complex in the activation of NF-κB, coupled with the druggability of kinases as a target class, numerous companies have been pursuing discovery programmes aimed at identifying small molecule inhibitors of these enzymes. This paper reviews the patenting activity associated with these efforts.
No takes yet. Share an insight, caveat, or question.
Coish et al. (2005) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: